Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06439589
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-05-28
Brief Title:
Phase IbII Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Sponsor:
Shanghai Hengrui Pharmaceutical Co Ltd
Organization:
Shanghai Hengrui Pharmaceutical Co Ltd
Study Overview
Official Title:
An Open-label Multi-center Phase IbII Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter open-label dose-findingefficacy-expanding phase IbII clinical trial which aims to observe and evaluate the tolerability safety pharmacokinetic characteristics and immunogenicity of HRS2398 combined with Adebrelimab injection in patients with advanced solid tumors determine the RP2D and preliminarily evaluate the efficacy of HRS2398 combined with Adebrelimab in patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None